OptiNose, Inc. (OPTN)
- Previous Close
9.52 - Open
9.59 - Bid 6.95 x 200
- Ask 12.32 x 200
- Day's Range
9.55 - 9.74 - 52 Week Range
4.82 - 20.02 - Volume
169,836 - Avg. Volume
94,056 - Market Cap (intraday)
98.135M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.12 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
www.optinose.com127
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: OPTN
View More
Performance Overview: OPTN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPTN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPTN
View MoreValuation Measures
Market Cap
96.62M
Enterprise Value
141.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.24
Price/Book (mrq)
--
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-36.52%
Return on Assets (ttm)
-9.97%
Return on Equity (ttm)
--
Revenue (ttm)
81.86M
Net Income Avi to Common (ttm)
-29.89M
Diluted EPS (ttm)
-2.12
Balance Sheet and Cash Flow
Total Cash (mrq)
72.93M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.15M